Results 151 to 160 of about 362,551 (290)
Th1-Mediated Intestinal Inflammation in Crohn's Disease May Be Induced by Activation of Lamina Propria Lymphocytes Through Synergistic Stimulation of Interleukin-12 and Interleukin-18 Without T Cell Receptor Engagement [PDF]
Akira Okazawa+8 more
openalex +3 more sources
Decrypting cancer's spatial code: from single cells to tissue niches
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik+4 more
wiley +1 more source
Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammation
Anthony O’Regan, Jeffrey S. Berman
openalex +2 more sources
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira+14 more
wiley +1 more source
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian+10 more
wiley +1 more source
Evidence for a perforin‐mediated mechanism controlling cardiac inflammation in Trypanosoma cruzi infection [PDF]
Andrea Henriques‐Pons+10 more
openalex +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga+8 more
wiley +1 more source